JMV 2959

Research use only, not for human use.

JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32 nM.

JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32 nM.(In Vitro):JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32 nM. JMV 2959 does not induce any intracellular calcium mobilization by itself.(In Vivo):When administered alone, it does not increase food intake and does not significantly stimulate growth hormone (GH) release. JMV 2959 dose dependently decreases the startle response (F(3.42)=4.4, p<0.01) and increases %prepulse inhibition (PPI) (F(3.42)=3.9, p<0.05) in the prepulse inhibition paradigm. The alteration in the startle response is mainly due to a 27% decrease in the startle seen in the highest dose of JMV 2959 (6 mg/kg) compare to vehicle (p<0.05). 6 mg/kg JMV 2959 induces a significant suppression of locomotion on days 1 to 7 relative to baseline day 0 (F(7,49)=2.21, p<0.05). Results also reveal a significant interaction between JMV 2959 treatment and day (F(1,14)=4.397, p<0.05).

——

——

JMV2959 | JMV 2959 | JMV-2959

GPCR/G Protein

GHSR

IC50: 32 nM (GHS-R1a)

——

——

925238-89-7

508.61

C??H??N?O?

>98% (HPLC)

Soluble in DMSO

O=C(N[C@@H](C1=NN=C(CCC2=CC=CC=C2)N1CC3=CC=C(OC)C=C3)CC4=CNC5=C4C=CC=C5)CN

N-[(R)-1-[4-(4-Methoxybenzyl)-5-phenethyl-4H-124-triazol-3-yl]-2-(1H-indol-3-yl)ethyl]-2-aminoacetamide

(-20℃)

With Ice Pack

≥ 2 years